Beta blocker shows cancer-fighting properties

April 23, 2017

A new study finds that carvedilol, a drug typically used to treat high blood pressure, can protect against the sun-induced cell damage that leads to skin cancer. Researchers serendipitously discovered the beta blocker's cancer-fighting properties after making an error in the lab.

Sherry Liang, a graduate student at the Western University of Health Sciences College of Pharmacy, will present the new findings at the American Society for Pharmacology and Experimental Therapeutics annual meeting during the Experimental Biology 2017 meeting, to be held April 22-26 in Chicago.

"What began as an experimental error led to a very interesting scientific discovery," said Ying Huang, PhD, coleader of the research team with Bradley T. Andresen, PhD. "Our research could lead to the development of a class of new cancer-preventive agents."

Carvedilol's cancer-fighting properties were discovered when a former in Huang's lab was studying whether carvedilol and similar beta blockers might increase cancer risk. The student inadvertently tested carvedilol's anticancer effect rather than its ability to promote cancer, finding that carvedilol surprisingly showed some protective effects against cancer.

The researchers then conducted experiments with cell cultures and mice to see if carvedilol could prevent skin cancer caused by ultraviolet-B (UVB), the portion of sunlight that tends to damage the skin's top epidermal layers and plays a key role in skin cancer development.

The video will load shortly.
A new study finds that carvedilol, a drug typically used to treat high blood pressure, can protect against the sun-induced cell damage that leads to skin cancer. Credit: Bradley T. Andresen PhD, Western University of Health Sciences

The researchers found that carvedilol exhibited a protective effect in cultured mouse skin cells exposed to UVB and in hairless mice given the drug after UVB exposure. The experiments showed that carvedilol acted by protecting cells against the cancer-causing DNA damage and cell death produced by UVB. Hairless mice exposed to UVB and given carvedilol showed decreases in both the severity and number of tumors that developed compared to those not given carvedilol. The mouse studies also showed that carvedilol delayed skin tumor formation more than sunscreen.

The researchers also discovered that not all beta blockers show cancer preventive properties, indicating that the cancer-fighting beta blockers likely act on not yet identified molecules. "We have preliminary data indicating that the cellular targets for carvedilol are not related to the beta-adrenergic receptors that are the commonly accepted targets for all beta blockers," said Andresen. "They likely target unexpected mechanisms involved in development."

The researchers aim to incorporate carvedilol or similar beta blockers into a skin cream or spray that could hopefully be used to prevent arising from UV light exposure. The treatment would act on the skin without affecting blood pressure and heart rate, which are commonly altered by . Understanding 's mechanisms of action could also allow scientists to design completely new treatments that target these mechanisms without introducing any cardiovascular effects.

Explore further: Beta-blockers may boost chemo effect in childhood cancer

More information: Experimental Biology 2017 meeting, app.core-apps.com/eb2017/abstr … 2834d471e29e288c1187
Experimental Biology 2017 meeting, app.core-apps.com/eb2017/abstr … 7b5a162e9981c25f1bfb

Related Stories

Beta-blockers may boost chemo effect in childhood cancer

May 22, 2013
Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, a type of children's cancer, according to a new study published in the British Journal of ...

Blood pressure drugs don't protect against colorectal cancer

May 14, 2012
A new study has found that, contrary to current thinking, taking beta blockers that treat high blood pressure does not decrease a person's risk of developing colorectal cancer. Published early online in CANCER, a peer-reviewed ...

Researchers discover a new way to keep the heart pumping, which could lead to new drugs for heart disease

June 27, 2016
About 5.7 million Americans have heart failure, half of whom will die from the disease within 5 years, according to the Centers for Disease Control and Prevention (CDC). Two processes help drive the disease: a weakened heart ...

Recommended for you

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

Scientists restore tumor-fighting structure to mutated breast cancer proteins

September 20, 2017
Scientists at the Virginia Tech Carilion Research Institute have successfully determined the full architecture of the breast cancer susceptibility protein (BRCA1) for the first time. This three-dimensional information provides ...

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

New clinical trial explores combining immunotherapy and radiation for sarcoma patients

September 20, 2017
University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.